N-Boc 4-nitropiperidine: preparation and conversion into a spiropiperidine analogue of the eastern part of maraviroc
摘要:
Previously unreported N-Boc 4-nitropiperidine was prepared in two steps from N-Boc-piperidone. The synthetic utility of this new intermediate was demonstrated by the development of a new and simple route to spirolactam piperidines. Further synthetic work involving a challenging triazole cyclisation allowed the preparation of a spiropiperidine analogue of the eastern part of maraviroc. (C) 2010 Elsevier Ltd. All rights reserved.
N-Boc 4-nitropiperidine: preparation and conversion into a spiropiperidine analogue of the eastern part of maraviroc
摘要:
Previously unreported N-Boc 4-nitropiperidine was prepared in two steps from N-Boc-piperidone. The synthetic utility of this new intermediate was demonstrated by the development of a new and simple route to spirolactam piperidines. Further synthetic work involving a challenging triazole cyclisation allowed the preparation of a spiropiperidine analogue of the eastern part of maraviroc. (C) 2010 Elsevier Ltd. All rights reserved.
[EN] HETEROCYCLIC AMIDE AND UREA COMPOUNDS AS JAK2 INHIBITORS<br/>[FR] COMPOSÉS D'URÉE ET D'AMIDE HÉTÉROCYCLIQUES EN TANT QU'INHIBITEURS DE JAK2
申请人:[en]AJAX THERAPEUTICS, INC.
公开号:WO2024035627A1
公开(公告)日:2024-02-15
The present disclosure provides heterocyclic amide and urea compounds and compositions thereof useful for inhibiting JAK2.
N-Boc 4-nitropiperidine: preparation and conversion into a spiropiperidine analogue of the eastern part of maraviroc
作者:Philip Mullen、Hugues Miel、M. Anthony McKervey
DOI:10.1016/j.tetlet.2010.04.046
日期:2010.6
Previously unreported N-Boc 4-nitropiperidine was prepared in two steps from N-Boc-piperidone. The synthetic utility of this new intermediate was demonstrated by the development of a new and simple route to spirolactam piperidines. Further synthetic work involving a challenging triazole cyclisation allowed the preparation of a spiropiperidine analogue of the eastern part of maraviroc. (C) 2010 Elsevier Ltd. All rights reserved.